2022 World Conference on Lung Cancer (ePosters)-EP08.02-050. A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

EP08.02-050. A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the efficacy of a combination therapy of Aumolertinib and bevacizumab in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM). The study included 5 patients with a median age of 54 years, mostly female. Prior to the combination therapy, the patients had received an average of 1.2 lines of therapy. The median length of therapy with Aumolertinib and bevacizumab was 11 months.<br /><br />The results of the study showed that the combination therapy resulted in a significant reduction of LM in all 5 patients, with continued remission of LM as the treatment continued. There was no progression of systemic or LM lesions in any of the patients. The neurological symptomatic response improved in all patients.<br /><br />The combination therapy of Aumolertinib and bevacizumab demonstrated high efficacy in patients with EGFR-mutated NSCLC and LM, even in patients with non-sensitive mutations and poor physical status. The treatment showed a rapid onset of action, sustained remission of meningeal lesions, and a long duration of remission.<br /><br />Overall, the study suggests that the combination therapy of Aumolertinib and bevacizumab could be an effective treatment option for patients with EGFR-mutated NSCLC and LM, improving patient outcomes and prognosis. Further research and clinical trials are needed to validate these findings.

Asset Subtitle

shencun Fang

Meta Tag

Speaker shencun Fang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

efficacy

combination therapy

Aumolertinib

bevacizumab

EGFR-mutated non-small cell lung cancer

leptomeningeal metastasis

patients

neurological symptomatic response

treatment option